HN21C0958

Development of functional hyaluronic acid nanoparticle lead compounds for treatment of skin inflammation

Ajou University

IMMUNOLOGY | Lead

Product Type	Hyaluronic acid-based Nanoparticle
Indication	1st indication: Psoriasis, 2nd indication: Contact dermatitis
Target	TLR4, CD44
MoA(Mechanism of Action)	Inflammation/immune response control through TLR inhibition 
Competitiveness	• HA-NP as distinctive physicochemical and biological characteristics, such as biocompatible, biodegradable, non-toxic, and receptor binding properties • HA-NP itself without any drug is a topical therapeutic agent that has anti-inflammatory activity and controls inflammatory diseases. • HA-NP can be administered transcutaneously.
Development Stage	Lead
Route of Administration	Topical, Subcutaneous, intravenus

kddf_bd@kddf.org
KDDF Business Development Team

KDDF Korea Drug Development Fund